In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SYMPLICITY Results Make Life Difficult For Renal Denervation Programs

Executive Summary

The big slice of the device industry, from large-cap firms to venture capitalists, with some stake in the renal denervation opportunity are trying to understand the new reality now that Medtronic’s pivotal Symplicity renal denervation device trial missed its endpoint.

Advertisement

Related Content

A Device For Hypertension After All?
A Device For Hypertension After All?
Vascular Interventional Devices: New Avenues For Growth
Eight Things That Will Fix Medtech Investing
Renal Denervation Downer: Medtronic’s Pivotal Trial Misses Efficacy Endpoint
Renal Denervation Land Grab Continues As Boston Scientific Buys Vessix
The Renal Denervation Buzz: Separating Fact From Myth; Covidien Buys Maya Medical
Device M&A Rebound Continues: With Ardian, Sadra Deals Show Appetite For Big, Early-Stage Acquisitions

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV004128

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel